Top Story

BRAF genotypes exhibit different clinical, pathologic profiles

March 28, 2017

NEW YORK — An analysis of the clinical and pathologic profiles of BRAF genotypes among individuals with melanoma revealed differences related to patient age at presentation, recurrence rates and disease-specific mortality, according to study results presented at HemOnc Today Melanoma and Cutaneous Malignancies.

Patients with BRAF V600K mutations experienced the highest recurrence rates, and all recurrences in this group were metastatic. However, they were less likely to die of melanoma, possibly due to older age at presentation and death from other comorbidities.

Meeting NewsVideo

VIDEO: Intralesional agent, immunotherapy combination may increase response in metastatic melanoma

March 27, 2017
NEW YORK — Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, surgical oncologist at Huntsman Cancer Institute, and a HemOnc Today Editorial Board member, discussed the…
FDA approvals

FDA approves Zejula for maintenance treatment of gynecologic cancers

March 27, 2017
The FDA today approved niraparib for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers who achieved…
In the Journals Plus

Close proximity to oil, gas development areas may increase risk for pediatric ALL

March 27, 2017
Young people living in Colorado diagnosed with acute lymphocytic leukemia were more likely to live in areas with a high-density of oil and gas development, according to…
In the Journals Plus

Imatinib confers long-term survival in patients with gastrointestinal stromal tumors

March 27, 2017
Imatinib treatment conferred a “durable, long-term” OS in nearly a quarter of patients with metastatic gastrointestinal stromal tumors, or GIST, according
More News Headlines »

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients…
More »
Meeting News

VIDEO: Decision to undergo lymph node dissection remains ‘complicated’

March 25, 2017
More »
HEMONC TODAY Melanoma and Cutaneous Malignancies

HEMONC TODAY Melanoma and Cutaneous Malignancies


Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
Current Issues
View the Current Issue
HemOnc Today